Northern Trust Corp Has $36.04 Million Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• Northern Trust Corp reduced its stake in Catalyst Pharmaceuticals by 1.2%, holding approximately $36.04 million worth of shares after selling 17,368 shares in the first quarter.
• Institutional investors hold 79.22% of Catalyst Pharmaceuticals' stock, indicating strong support from larger financial entities.
• Analysts have mixed ratings on Catalyst Pharmaceuticals, with two giving it a "Strong Buy" rating and a consensus rating of "Buy" overall, along with an average target price of $33.20.

Northern Trust Corp trimmed its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 1.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,486,198 shares of the biopharmaceutical company's stock after selling 17,368 shares during the quarter. Northern Trust Corp owned about 1.22% of Catalyst Pharmaceuticals worth $36,040,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in CPRX. State of Tennessee Department of Treasury increased its holdings in shares of Catalyst Pharmaceuticals by 4.5% during the fourth quarter. State of Tennessee Department of Treasury now owns 50,587 shares of the biopharmaceutical company's stock valued at $1,056,000 after purchasing an additional 2,193 shares during the period. Hsbc Holdings PLC boosted its holdings in shares of Catalyst Pharmaceuticals by 64.7% in the fourth quarter. Hsbc Holdings PLC now owns 36,337 shares of the biopharmaceutical company's stock worth $764,000 after buying an additional 14,269 shares during the period. Susquehanna International Group LLP raised its stake in Catalyst Pharmaceuticals by 2.4% during the 4th quarter. Susquehanna International Group LLP now owns 99,213 shares of the biopharmaceutical company's stock valued at $2,071,000 after purchasing an additional 2,291 shares during the period. Voya Investment Management LLC lifted its stake in Catalyst Pharmaceuticals by 24.9% in the 4th quarter. Voya Investment Management LLC now owns 52,416 shares of the biopharmaceutical company's stock worth $1,094,000 after acquiring an additional 10,465 shares in the last quarter. Finally, Tudor Investment Corp ET AL acquired a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth approximately $1,243,000. Institutional investors and hedge funds own 79.22% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on CPRX shares. Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. Finally, Zacks Research downgraded shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $33.20.

Insider Activity

In related news, insider Steve Miller sold 115,000 shares of the business's stock in a transaction that occurred on Tuesday, August 26th. The shares were sold at an average price of $20.28, for a total transaction of $2,332,200.00. Following the completion of the sale, the insider directly owned 949,663 shares of the company's stock, valued at $19,259,165.64. The trade was a 10.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Preethi Sundaram sold 1,600 shares of the company's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total transaction of $42,272.00. Following the completion of the sale, the insider directly owned 41,081 shares of the company's stock, valued at $1,085,360.02. The trade was a 3.75% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 167,894 shares of company stock worth $3,434,690. Corporate insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Price Performance

Shares of Catalyst Pharmaceuticals stock traded down $0.77 during midday trading on Wednesday, hitting $19.78. 1,394,606 shares of the company were exchanged, compared to its average volume of 1,311,964. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.00 and a 52 week high of $26.58. The firm has a 50 day simple moving average of $20.96 and a 200-day simple moving average of $22.48. The firm has a market cap of $2.42 billion, a P/E ratio of 11.96, a PEG ratio of 0.84 and a beta of 0.85.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.